1 BTC
=
- USD
GeoVax Labs, Inc. New
As of May 30, 2026 at 24:05 UTC
Chart
About GeoVax Labs, Inc. New
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Market Statistics
Trading Metrics
How to Buy GOVX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy GOVX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesFollowing the WHO's declaration of a Public Health Emergency for the Bundibugyo virus Ebola outbreak on May 17, 2026, biodefense diagnostics companies are experiencing significant capital inflows. Co-Diagnostics is positioned as a strategic play due to its decentralized manufacturing network through joint ventures in India (CoSara) and Saudi Arabia (CoMira), which addresses national security demands for localized production. The company is advancing PCR assays for Ebola detection and has near-term catalysts including FDA 510(k) submission and India TB test commercialization in Q3 2026, though the stock's recent 200%+ surge on low float presents both opportunity and volatility.
The WHO Africa regional director Mohamed Yakub Janabi warned against underestimating the Ebola outbreak in the Democratic Republic of Congo, which has reported 670 suspected cases and 61 confirmed infections. The Bundibugyo strain has no approved vaccine and has already spread to Uganda. Containment efforts are hampered by population movement, misinformation, and community mistrust. Former CDC Director Robert Redfield warned the outbreak could become a significant pandemic.
GeoVax Labs (GOVX) shares surged 16.42% to $2.34 as the company highlighted its MVA vaccine platform's potential to address emerging Ebola and hemorrhagic fever threats, following a WHO emergency declaration. The company announced a $3 million private placement and plans Phase 3 testing of its mpox and smallpox vaccine candidate in Q4 2026. Despite the rally, the stock remains down 91% over the past 12 months.
